The OASE study
Key facts
- Where
- Aalborg és Hjoerring, DániaSee the 2 sites
- Phase
- 4. fázis
Where in Dánia
- Aalborg University HospitalAalborg, DániaToborzás még nem indult
- Regionshospital NordjyllandHjoerring, DániaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Aalborg University Hospital
- Trial code
- EU 2026-525221-21-01
- Record updated
- 2026. július 6.
- Original description
The co-primary objective is to evaluate cs-/b-/tsDMARD tapering (tapering group) compared to continuation of DMARDs as usual care (control group) based on patient preference in elderly patients (≥70 years) with RA in sustained LDA. The co-primary endpoint at 24 months will be met if: A. Superiority in ≥50% accumulated cs- and/or b-/tsDMARD dose reduction is demonstrated in the tapering group compared to the control group. The accumulated DMARD dose reduction will be calculated as the mean percentage reduction across cs- and b-/tsDMARD treatments relative to the baseline dosing. E.g., 25% reduction in csDMARD and 25% reduction in b-/tsDMARD = 25% total DMARD reduction, 100% reduction in cs-DMARD and 0% in b-/tsDMARD = 50% total reduction, and 75% reduction in cs-DMARD and 50% in b-/ts-DMARD = 63% total reduction. B. Equivalent disease activity is maintained measured by the average Disease Activity Score-28-C-Reactive Protein score (DAS28-CRP) across the 24-months observation period with predefined equivalence margins of ±0.5.Read full original descriptionShow less
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
The co-primary objective is to evaluate cs-/b-/tsDMARD tapering (tapering group) compared to continuation of DMARDs as usual care (control group) based on patient preference in elderly patients (≥70 years) with RA in sustained LDA. The co-primary endpoint at 24 months will be met if: A. Superiority in ≥50% accumulated cs- and/or b-/tsDMARD dose reduction is demonstrated in the tapering group compared to the control group. The accumulated DMARD dose reduction will be calculated as the mean percentage reduction across cs- and b-/tsDMARD treatments relative to the baseline dosing. E.g., 25% reduction in csDMARD and 25% reduction in b-/tsDMARD = 25% total DMARD reduction, 100% reduction in cs-DMARD and 0% in b-/tsDMARD = 50% total reduction, and 75% reduction in cs-DMARD and 50% in b-/ts-DMARD = 63% total reduction. B. Equivalent disease activity is maintained measured by the average Disease Activity Score-28-C-Reactive Protein score (DAS28-CRP) across the 24-months observation period with predefined equivalence margins of ±0.5.